<< Back
U.S. Hospital Surpasses 1,000 Procedures using Stereotaxis Niobe® System
April 4, 2016 at 9:01 AM EDT
Saint Francis Leads New England in Treatment with Remote Magnetic Navigation    

ST. LOUIS, April 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has completed more than 1,000 cardiac ablation procedures using its Niobe® remote magnetic navigation system. Drs. Joseph Dell’Orfano and Aneesh Tolat, electrophysiologists with Arrhythmia Consultants of Connecticut, were among the early adopters of the Niobe system and each has surpassed 500 procedures on the system, making the hospital the leading site in New England to use Stereotaxis technology.

“Utilizing the Niobe ES system, we can navigate a catheter safely and accurately within any of the four chambers of the heart, with nearly no danger of perforation and more consistent contact between the catheter and heart wall, resulting in more effective ablations,” said Dr. Dell’Orfano.

“The benefits of Stereotaxis technology are far greater than conventional methods used to treat arrhythmias. The unique design of remote magnetic navigation has greatly advanced our capabilities and reputation as a best-in-class institution for cardiac electrophysiology,” added Dr. Tolat.  

Saint Francis first installed the Niobe system in 2007 and then in early 2012 upgraded to the Niobe ES, the latest generation magnetic navigation platform. The hospital helped pioneer the practice of remote magnetic navigation for electrophysiology procedures in New England, providing feedback and expertise during early usage. Led by Drs. Tolat and Dell’Orfano, Saint Francis has performed more procedures with the Niobe system than any hospital in the region, primarily for complex left atrial and supraventricular tachycardia cases.  

About Electrophysiology
Electrophysiology (EP) is often used to help correct heart arrhythmias through catheter ablation, which is a treatment that cauterizes (burns) cardiac tissue to eliminate rhythm abnormalities in patients. During an EP procedure, the electrophysiologist (a cardiologist with specialized training in the electrical system of the heart) threads special electrode catheters (long, thin, flexible wire assemblies) to the heart, normally gaining access to the vasculature through the groin area. Once the area of the heart responsible for the arrhythmia is identified, a special wire carrying radiofrequency energy is used to ablate the site.

About Saint Francis
Saint Francis Hospital and Medical Center has been an anchor institution in north central Connecticut since 1897. In 2015, Saint Francis became part of Trinity Health-New England, an integrated health care delivery system that is a member of Trinity Health, Livonia, MI, one of the largest multi-institutional Catholic health care delivery systems in the nation. Saint Francis Hospital is a major teaching hospital and the largest Catholic hospital in New England. Other Saint Francis entities include the Comprehensive Women’s Health Center, the Connecticut Joint Replacement Institute, the Hoffman Heart and Vascular Institute of Connecticut, Smilow Cancer Hospital Yale-New Haven at Saint Francis, and Saint Francis Medical Group.

About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.

The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono ICE catheter manipulator, V-Loop variable loop catheter manipulator, and V-CAS catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

STXS Company Contact:
Martin Stammer
Chief Financial Officer

STXS Investor Contact:
Todd Kehrli / Jim ByersMKR Group, Inc.

Saint Francis Contact:
Fiona Phelan
Media Relations Manager

Primary Logo

Stereotaxis, Inc.
© Copyright Stereotaxis 2020